![]() ![]() However, in April, the stock took a dive after underwhelming data from this program. Post treatment, 4 out of 5 patients remained eylea injection free at between 16 and 40 weeks. In wet AMD trials, treatment sharply reduced eylea burden in patients who were previously taking 11 yearly injections on average. So they have a vector and a transgene, and early trials showed that the vectors were able to deliver the respective transgenes deep into targeted tissues (the vector worked), where there was strong transgene expression (the drug worked). This is an AAV vector platform targeting three disease areas: ophthalmology, cardiology and pulmonology.įDMT has five product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa ("XLRP"), 4D-150 for the treatment of wet age-related macular degeneration ("wet AMD"), 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, and 4D-710 for the treatment of cystic fibrosis lung disease. One key reason for that is the clinical hold that the FDA slapped on its Fabry Disease program after 3 patients developed a serious kidney condition.įDMT is a gene therapy developer with a novel vector technology developed at UC Berkeley, from where they licensed certain foundational libraries of these vectors. ( NASDAQ: FDMT) in January, there’s been a slew of articles on Seeking Alpha, and yet, the stock is down 40%. After our early article on 4D Molecular Therapeutics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |